TFF Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q3 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
TFF Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2018 to Q3 2024.
  • TFF Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.58M, a 19% increase year-over-year.
  • TFF Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$18.7M, a 21.8% increase year-over-year.
  • TFF Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$21.9M, a 31.1% increase from 2022.
  • TFF Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$31.8M, a 0.03% decline from 2021.
  • TFF Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$31.8M, a 70% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$18.7M -$3.58M +$839K +19% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-20
Q2 2024 -$19.5M -$3.96M +$1.06M +21% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$20.6M -$5.79M +$1.3M +18.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$21.9M -$5.37M +$2.01M +27.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$23.9M -$4.42M +$2.86M +39.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-20
Q2 2023 -$26.8M -$5.02M +$3.73M +42.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$30.5M -$7.09M +$1.3M +15.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$31.8M -$7.38M +$2.72M +26.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$34.5M -$7.28M +$1.4M +16.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$35.9M -$8.75M -$3.64M -71.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$32.3M -$8.38M -$482K -6.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$31.8M -$10.1M -$4.18M -70.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$27.6M -$8.68M -$3.6M -70.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$24M -$5.11M -$1.27M -33% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$22.7M -$7.9M -$4.05M -105% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 -$18.7M -$5.92M -$1.21M -25.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 -$17.5M -$5.08M -$2.21M -77.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$15.3M -$3.84M -$1.63M -73.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$13.6M -$3.85M -$1.65M -75% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$12M -$4.71M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-10
Q3 2019 -$2.86M -$2.26M -373% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$2.21M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$2.2M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q3 2018 -$606K Jul 1, 2018 Sep 30, 2018 10-Q 2019-12-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.